Journal
CELLS
Volume 10, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/cells10010014
Keywords
cancer; metabolic reprogramming; combined therapy; Chimeric Antigen Receptor T cells; immunotherapy
Categories
Funding
- Fondazione Mia Neri
- Fondazione Umberto Veronesi
- Associazione Italiana Ricerca sul Cancro (AIRC)-Start-Up Grant [17184]
- Interdisziplinare Zentrum fur Klinische Forschung (IZKF) Wurzburg [Z-4/147]
Ask authors/readers for more resources
The adoptive transfer of CAR-expressing T cells has shown unprecedented success in treating B-cell malignancies, but its efficacy in other types of cancers is still limited. The metabolic fitness of CAR T cells plays a crucial role in their ability to target and function within solid tumors, with both tumor and T cell metabolism impacting the immune response significantly.
The adoptive transfer of the chimeric antigen receptor (CAR) expressing T-cells has produced unprecedented successful results in the treatment of B-cell malignancies. However, the use of this technology in other malignancies remains less effective. In the setting of solid neoplasms, CAR T-cell metabolic fitness needs to be optimal to reach the tumor and execute their cytolytic function in an environment often hostile. It is now well established that both tumor and T cell metabolisms play critical roles in controlling the immune response by conditioning the tumor microenvironment and the fate and activity of the T cells. In this review, after a brief description of the tumoral and T cell metabolic reprogramming, we summarize the latest advances and new strategies that have been developed to improve the metabolic fitness and efficacy of CAR T-cell products.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available